Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of either open angle glaucoma or ocular hypertension.~* Currently on beta-blocker monotherapy (for \>30 days) and would benefit, in the opinion of the investigator, from further intraocular pressure (lOP) reduction.~* Have a mean baseline lOP of \>18 mmHg and \<32 mmHg in at least one eye.~* Must be able to understand and sign an Informed Consent form.~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Use of medication excluded by the protocol.~* Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol.~* Ocular surgeries or procedures excluded by the protocol.~* Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen, 0.60 logMAR or 0.25 decimal).~* Hypersensitivity to prostaglandin analogues or any component of the study medications in the opinion of the investigator.~* Women of childbearing potential if pregnant, test positive for pregnancy at Screening visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
- Beta-blocker (Type: ACTIVE_COMPARATOR): Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).